Five Prime Therapeutics (NASDAQ:FPRX) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Saturday.
Several other analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, March 2nd. BMO Capital Markets reduced their price target on shares of Five Prime Therapeutics from $75.00 to $60.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 28th. Nomura reduced their price target on shares of Five Prime Therapeutics from $94.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, February 28th. Finally, ValuEngine cut shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Three analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $47.20.
Shares of Five Prime Therapeutics (FPRX) opened at $16.12 on Friday. The stock has a market cap of $570.67, a PE ratio of -3.00 and a beta of 3.33. Five Prime Therapeutics has a 1 year low of $15.82 and a 1 year high of $48.87.
TRADEMARK VIOLATION NOTICE: This article was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://stocknewstimes.com/2018/03/17/five-prime-therapeutics-fprx-lowered-to-strong-sell-at-bidaskclub.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.